Search

Dutch scientists propose algorithm to keep drugs affordable and accessible

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

Read more

EHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials

EHA has responded to the EMA’s call for comments on the reflection paper on February 15.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more